Controls severe or incapacitating allergic conditions. ANDA 203559, held by Edenbridge Pharms. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 203559 (Prednisolone Sodium Phosphate), held by Edenbridge Pharms, was first approved by FDA on Dec 20, 2016, with 1 approved supplement and 0 published complete response letters.
INDICATIONS & USAGE Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL), Prednisolone Sodium Phosphate Oral Solution (15 mg Prednisolone per 5 mL), Prednisolone Sodium Phosphate Oral Solution (20 mg Prednisolone per 5 mL) and Prednisolone Sodium Phosphate (25 mg Prednisolone per 5 mL) are indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 20, 2016 | Original application | Approved |
| Prednisolone Sodium PhosphateEQ 10MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Prednisolone Sodium PhosphateEQ 20MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Prednisolone Sodium PhosphateEQ 15MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Prednisolone Sodium PhosphateEQ 25MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 20, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters